Cargando…

Up-regulation of fas reverses cisplatin resistance of human small cell lung cancer cells

BACKGROUND/AIM: Fas/FasL system is a major regulator of apoptosis. The mechanisms by which Fas mediates cisplatin resistance remain unclear. The aim of this study is to explore the effect of Fas over-expression on cisplatin resistance of small cell lung cancer cells and its possible mechanisms. MATE...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Wei, Wang, Hai-dong, Guo, Wei, Yang, Kang, Zhao, Yun-ping, Jiang, Yao-guang, He, Ping
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2877011/ https://www.ncbi.nlm.nih.gov/pubmed/20470393 http://dx.doi.org/10.1186/1756-9966-29-49

Ejemplares similares

Upregulation of Fas in epithelial ovarian cancer reverses the development of resistance to Cisplatin
por: Yang, Fan, et al.
Publicado: (2015)

Retrospective study of irinotecan/cisplatin followed by etoposide/cisplatin or the reverse sequence in extensive-stage small cell lung cancer
por: Xiao, Xiaoguang, et al.
Publicado: (2015)

Piperlongumine Inhibits Akt Phosphorylation to Reverse Resistance to Cisplatin in Human Non-Small Cell Lung Cancer Cells via ROS Regulation
por: Zhang, Chao, et al.
Publicado: (2019)

Cordycepin Reverses Cisplatin Resistance in Non-small Cell Lung Cancer by Activating AMPK and Inhibiting AKT Signaling Pathway
por: Liao, Xiao-Zhong, et al.
Publicado: (2021)

Reversal of Cisplatin Resistance with Amphotericin B in a Non‐small Cell Lung Cancer Cell Line
por: Morikage, Toshihiko, et al.
Publicado: (1991)

PD‐0332991 combined with cisplatin inhibits nonsmall cell lung cancer and reversal of cisplatin resistance
por: Liu, Minghui, et al.
Publicado: (2021)

RNA interferences targeting the Fanconi anemia/BRCA pathway upstream genes reverse cisplatin resistance in drug-resistant lung cancer cells
por: Dai, Chun-Hua, et al.
Publicado: (2015)

HAT1 induces lung cancer cell apoptosis via up regulating Fas
por: Han, Na, et al.
Publicado: (2017)

Rosmarinic acid reverses non‐small cell lung cancer cisplatin resistance by activating the MAPK signaling pathway
por: Liao, Xiao‐Zhong, et al.
Publicado: (2020)

Co-inhibition of pol θ and HR genes efficiently synergize with cisplatin to suppress cisplatin-resistant lung cancer cells survival
por: Dai, Chun-Hua, et al.
Publicado: (2016)

Arsenic sulfide reverses cisplatin resistance in non‐small cell lung cancer in vitro and in vivo through targeting PD‐L1
por: Tian, Wei, et al.
Publicado: (2021)

miR-133b reverses cisplatin resistance by targeting GSTP1 in cisplatin-resistant lung cancer cells
por: Lin, Chen, et al.
Publicado: (2018)

JAK2 inhibitor combined with DC-activated AFP-specific T-cells enhances antitumor function in a Fas/FasL signal-independent pathway
por: Liu, Yang, et al.
Publicado: (2016)

Delicaflavone Reverses Cisplatin Resistance via Endoplasmic Reticulum Stress Signaling Pathway in Non-Small Cell Lung Cancer Cells
por: Wang, Xuewen, et al.
Publicado: (2020)

Downregulation of HIF-2α Reverse the Chemotherapy Resistance of Lung Adenocarcinoma A549 Cells to Cisplatin
por: Gao, Zhao-jia, et al.
Publicado: (2018)

TNFα sensitizes neuroblastoma cells to FasL-, cisplatin- and etoposide-induced cell death by NF-κB-mediated expression of Fas
por: Galenkamp, Koen MO, et al.
Publicado: (2015)

Effect of Wenxia Changfu Formula Combined With Cisplatin Reversing Non-Small Cell Lung Cancer Cell Adhesion-Mediated Drug Resistance
por: Wang, Meng-Ran, et al.
Publicado: (2020)

The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells
por: Guo, Jiwei, et al.
Publicado: (2018)

TRIB2 contributes to cisplatin resistance in small cell lung cancer
por: Liang, Yuanxin, et al.
Publicado: (2017)

Combination of siRNA-directed Gene Silencing With Cisplatin Reverses Drug Resistance in Human Non-small Cell Lung Cancer
por: Ganesh, Shanthi, et al.
Publicado: (2013)

MMP9 Expression Correlates With Cisplatin Resistance in Small Cell Lung Cancer Patients
por: Wu, Longqiu, et al.
Publicado: (2022)

Increased ABCC2 expression predicts cisplatin resistance in non‐small cell lung cancer
por: Chen, Yun, et al.
Publicado: (2020)

FIGNL1 is overexpressed in small cell lung cancer patients and enhances NCI-H446 cell resistance to cisplatin and etoposide
por: Ma, Jian, et al.
Publicado: (2017)

Demethoxycurcumin increases the sensitivity of cisplatin-resistant non-small lung cancer cells to cisplatin and induces apoptosis by activating the caspase signaling pathway
por: Chen, Yun, et al.
Publicado: (2020)

Reverse signaling by FasL inhibits primary human T cell activation
por: Paulsen, M, et al.
Publicado: (2009)

The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand
Publicado: (1996)

Disruption of the MDM2–p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway
por: Koster, R, et al.
Publicado: (2011)

Norcantharidin reverses cisplatin resistance and inhibits the epithelial mesenchymal transition of human non-small lung cancer cells by regulating the YAP pathway
por: Jin, Dan, et al.
Publicado: (2018)

Targeting HDAC/OAZ1 axis with a novel inhibitor effectively reverses cisplatin resistance in non-small cell lung cancer
por: Sun, Yuhong, et al.
Publicado: (2019)

Norcantharidin reverses cisplatin resistance and inhibits the epithelial mesenchymal transition of human non-small lung cancer cells by regulating the YAP pathway
por: Jin, Dan, et al.
Publicado: (2021)

Elevated Cellular PD1/PD-L1 Expression Confers Acquired Resistance to Cisplatin in Small Cell Lung Cancer Cells
por: Yan, Fei, et al.
Publicado: (2016)

Novel mechanism of harmaline on inducing G2/M cell cycle arrest and apoptosis by up-regulating Fas/FasL in SGC-7901 cells
por: Wang, Yihai, et al.
Publicado: (2015)

Licochalcone A up-regulates of FasL in mesenchymal stem cells to strengthen bone formation and increase bone mass
por: Ming, Leiguo, et al.
Publicado: (2014)

MicroRNAs as regulators of cisplatin-resistance in non-small cell lung carcinomas
por: Fadejeva, Irina, et al.
Publicado: (2017)

Skp2-mediated MLKL degradation confers cisplatin-resistant in non-small cell lung cancer cells
por: Zhou, Huiling, et al.
Publicado: (2023)

Yu Ping Feng San reverses cisplatin-induced multi-drug resistance in lung cancer cells via regulating drug transporters and p62/TRAF6 signalling
por: Lou, Jian-Shu, et al.
Publicado: (2016)

EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations
por: Gao, Jing, et al.
Publicado: (2016)

Predictable Resistance and Overall Survival of Gemcitabine/Cisplatin by Platelet Activation Index in Non-Small Cell Lung Cancer
por: Shi, Liang, et al.
Publicado: (2018)

Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p
por: Tian, Lin-Juan, et al.
Publicado: (2019)

Fas and Fas Ligand Interactions Suppress Melanoma Lung Metastasis
por: Owen-Schaub, Laurie B., et al.
Publicado: (1998)

Cannot write session to /tmp/vufind_sessions/sess_nkk17agr6om15j4nrp8blilfpq